As previously reported, Deutsche Bank downgraded Novo Nordisk (NVO) to Hold from Buy with a price target of DKK 275, down from DKK 400, after a miss in the REDEFINE4 trial. The firm had viewed non-inferiority in the R4 trial as a “requisite minimum” and it has materially reduced estimates following the trial results as the analyst is “throwing in the towel.”
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk downgraded to Hold from Buy at Deutsche Bank
- Novo Nordisk’s CagriSema Misses Non‑Inferiority Goal but Delivers 23% Weight Loss in REDEFINE 4 Trial
- Novo Nordisk (NVO) Drops 13% after CagriSema Misses Eli Lilly (LLY) in Head-to-Head Obesity Trial
- Novo Nordisk announces REDEFINE 4 trial did not achieve primary endpoint
- Novo Nordisk Calls Hybrid Annual General Meeting and Proposes New Board Members for March 26, 2026